Advisory Board
Advisory Board
Oliver Sartor, MD
Alton “Oliver” Sartor is director of the newly established Transformational Prostate Cancer Research Center in Louisiana, where he will be responsible for both providing direct patient care and continuing his groundbreaking research, with a primary focus on improving both the longevity and quality of life for men battling prostate cancer. He previously served as Professor of Medical Oncology and Director of Radiopharmaceutical Trials at Mayo Clinic in Rochester, MN, and prior to that as Laborde Professor of Medicine and Urology and Medical Director of the Tulane Cancer Center in New Orleans, LA. An internationally recognized prostate cancer specialist, he earned his MD with honors at Tulane University School of Medicine and completed his training at the University of Pennsylvania, Tulane, and the National Cancer Institute. He subsequently focused his clinical practice and research on prostate malignancies.
Dr Sartor has led or co-led numerous clinical trials, including four pivotal phase III studies that supported US FDA approvals for advanced prostate cancer therapies. His scholarship encompasses more than 500 publications, with significant contributions to the development and evaluation of radiopharmaceutical agents such as radium-223 and lutetium-177 PSMA-targeted treatments. In recognition of his leadership in practice-changing radiopharmaceutical trials, he was named an honorary member of the American Society of Radiation Oncology (ASTRO) in 2023 and has been invited to lecture in at least 33 countries.
Simron Singh, MD, MPH, FRCPC
Dr. Simron Singh is a Professor of Medicine at the University of Toronto and a medical oncologist at Odette Cancer Center, Sunnybrook Health Sciences Center in Toronto, Canada. He holds the University of Toronto/Sunnybrook Health Sciences Chair in Neuroendocrine Cancer Care and Research.
He completed his B. Sc as well as MD at University of Alberta in Edmonton, Alberta. He completed postgraduate training in Internal Medicine at Queens University in Kingston, Ontario, Canada and Medical Oncology at the University of Toronto. After completing his clinical training, Dr. Singh completed his Master's degree in Public Health from Harvard University in Boston, MA, USA
Dr. Singh is a global leader and expert in the field of Neuroendocrine cancers. He continues to create and lead major practice changing global clinical trials as well as guidelines. Besides being an international sought after speaker he has published in numerous high impact journals in this area including Lancet, Journal of Clinical Oncology and JAMA. He co-established the Susan Leslie clinic for neuroendocrine cancers – the first of its kind in the region. He is the president of the North American Neuroendocrine Society as well as co-head of the Commonwealth Neuroendocrine Tumor Society
